(NASDAQ: GRFS) Grifols Sa's forecast annual revenue growth rate of 2.33% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.12%.
Grifols Sa's revenue in 2025 is $8,013,757,777.On average, 16 Wall Street analysts forecast GRFS's revenue for 2025 to be $5,221,979,526,260, with the lowest GRFS revenue forecast at $5,008,837,504,780, and the highest GRFS revenue forecast at $5,473,624,622,588. On average, 16 Wall Street analysts forecast GRFS's revenue for 2026 to be $5,536,192,119,216, with the lowest GRFS revenue forecast at $5,197,227,549,572, and the highest GRFS revenue forecast at $5,923,285,532,420.
In 2027, GRFS is forecast to generate $5,917,097,538,248 in revenue, with the lowest revenue forecast at $5,519,003,246,516 and the highest revenue forecast at $6,383,259,765,872.